The Global Pain Management Devices Market size is estimated at USD 10.64 billion in 2024, and is expected to reach USD 16.89 billion by 2029, growing at a CAGR of 9.70% during the forecast period (2024-2029).
COVID-19 pandemic has had a substantial impact on the pain management devices market initially. The lockdown and strict laws imposed by the government impacted the growth of the pain management devices market.Due to some unforeseen reasons, the growth of this market was severely obstructed during the initial COVID-19 phase. However, the market gained traction due to the significant increase in infusion appointments, and ablation procedures which increased the market for pain management devices globally. Also, most of the pain management devices were deemed to be not so urgent, also all the outpatient and interventional procedures were reduced due to the strict lockdown imposed by the government, and thus the pain management device market was greatly impacted.
A significant increase in COVID-19 cases had also indirectly increased the number of patients suffering from pain worlwide. It was reported that pain was the first symptom of COVID-19, including myalgias, back pain, and headache. For instance, Best Practice and Research in Clinical Anaesthesiology, July 2020, reported that the majority of the COVID-19 patients had musculoskeletal, back pain, and headaches as a symptom. In another instance, the journal Scientific Reports, states that post-covid pain scores increased to 6 on a 10 scale as compared to pre-covid which was 5 on a 10. To manage and overcome the pain associated with COVID-19, people were more drifted towards pain management devices rather than medicines due to their less severe effects which subsequently led the healthcare industry to increase the manufacture of the pain management devices, which has driven this market.
The rise in cases of chronic diseases such as cancer and other cardiovascular diseases also boosted these devices to manage pain well, which has driven the pain management devices market. For instance, as per the data published by World Health Organization about 10 million deaths due to cancer were reported in 2020. The incidence of cancer is rising dramatically over the past few years and chronic pain associated as a symptom of this disease is also increasing, which is directly driving the pain management devices market.
One of the pain management device, pain controlled analgesia (PCA) pumps, are used to manage post-operative pain to overcome the pain associated with spine surgeries and some critical joint surgeries. For instance, National Spinal Cord Injury Statistical Center (NSCISC) 2021 datasheet has accounted the annual incidence of spinal cord injuries at 60 cases per million. With the increasing number of these cases, and a number of surgical procedures performed the demand for infusion and PCA pumps has significantly increased and thus has driven the pain management devices market.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period. However, still few patients prefer pain management drugs over devices due to a lack of awareness which may cause hindrance to the management devices market. Also, these devices are used for the treatment of second-line of therapy to overcome pain, which is another challenge for this market.
The increase in cases of COVID-19 had witnessed an increase in the symptoms of chronic pain including neuropathic pain. For instance, the article titled 'Potential for the increased prevalence of neuropathic pain after the COVID-19 pandemic' in the journal Pain Reports 2021, states that COVID-19 also causes peripheral or central neurological complications of neuropathic pain. Increased complications of COVID-19 including in particular Guillain-Barré syndrome, myelitis, and stroke are reviewed with regards to their potential risk of chronic neuropathic pain. This increase in the prevalence of chronic neuropathic pain after COVID-19 is another reason boosting the market growth.
Traditional therapy for pain management includes drugs and medicine, but due to the side effects associated with drugs, people are shifting towards neurostimulation pain management devices to overcome neuropathic pain. Thus because of the above-mentioned reasons neuropathic pain management devices segment is witnessing the largest share in this pain management devices segment.
The United States accounts for the increasing number of individuals suffering from pain. For instance, the Journal of Pain and Palliative Therapy, 2021 accounts that approximately 20.28% of the United States population is suffering from chronic pain and 5% of this population comprises adults who are suffering from high-impact chronic pain. Therefore, with the increasing prevalence of the population suffering from chronic pain in the United States rapidly drives its market for pain management devices. Also due to the high prevalence of neuropathic pain and higher incidence of the chronic disease reported in the United States, the population there is more dependent on pain management devices rather than on medicines. For instance, according to an article in the journal Pain Medicine, about 2% of the United States population suffers from neuropathic pain. Additionally, as the article in journal International Journal of Environmental Health and Public Resource, 2021 mentioned that approximately 45%, (or 133 million) of all Americans suffer from at least one chronic disease thus due to the high prevalence of population in North America suffering from chronic diseases. The increase in patient population suffering from pain will in turn propel the market growth.
Due to high growth potential, a significant increase in the patient base population, and high disposable income the demand of the pain management devices market is expected to increase during the forecast period.
This product will be delivered within 2 business days.
COVID-19 pandemic has had a substantial impact on the pain management devices market initially. The lockdown and strict laws imposed by the government impacted the growth of the pain management devices market.Due to some unforeseen reasons, the growth of this market was severely obstructed during the initial COVID-19 phase. However, the market gained traction due to the significant increase in infusion appointments, and ablation procedures which increased the market for pain management devices globally. Also, most of the pain management devices were deemed to be not so urgent, also all the outpatient and interventional procedures were reduced due to the strict lockdown imposed by the government, and thus the pain management device market was greatly impacted.
A significant increase in COVID-19 cases had also indirectly increased the number of patients suffering from pain worlwide. It was reported that pain was the first symptom of COVID-19, including myalgias, back pain, and headache. For instance, Best Practice and Research in Clinical Anaesthesiology, July 2020, reported that the majority of the COVID-19 patients had musculoskeletal, back pain, and headaches as a symptom. In another instance, the journal Scientific Reports, states that post-covid pain scores increased to 6 on a 10 scale as compared to pre-covid which was 5 on a 10. To manage and overcome the pain associated with COVID-19, people were more drifted towards pain management devices rather than medicines due to their less severe effects which subsequently led the healthcare industry to increase the manufacture of the pain management devices, which has driven this market.
The rise in cases of chronic diseases such as cancer and other cardiovascular diseases also boosted these devices to manage pain well, which has driven the pain management devices market. For instance, as per the data published by World Health Organization about 10 million deaths due to cancer were reported in 2020. The incidence of cancer is rising dramatically over the past few years and chronic pain associated as a symptom of this disease is also increasing, which is directly driving the pain management devices market.
One of the pain management device, pain controlled analgesia (PCA) pumps, are used to manage post-operative pain to overcome the pain associated with spine surgeries and some critical joint surgeries. For instance, National Spinal Cord Injury Statistical Center (NSCISC) 2021 datasheet has accounted the annual incidence of spinal cord injuries at 60 cases per million. With the increasing number of these cases, and a number of surgical procedures performed the demand for infusion and PCA pumps has significantly increased and thus has driven the pain management devices market.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period. However, still few patients prefer pain management drugs over devices due to a lack of awareness which may cause hindrance to the management devices market. Also, these devices are used for the treatment of second-line of therapy to overcome pain, which is another challenge for this market.
Pain Management Devices Market Trends
The neuropathic pain management devices segment counted for the largest share of the global market and witness significant growth
Neuropathic pain can happen if the nervous system is damaged or not working correctly. The neuropathic pain management device segment has witnessed dominance in this pain management devices market. The growth of neuropathic pain management devices has increased attributed due to the increase in the prevalence population of neuropathic pain. For instance, the Centers for Disease Control and Center, 2021 reports that about one in five adults suffers from neuropathic pain. Due to an increase in the incidence rate of the population dealing with neuropathic painThe increase in cases of COVID-19 had witnessed an increase in the symptoms of chronic pain including neuropathic pain. For instance, the article titled 'Potential for the increased prevalence of neuropathic pain after the COVID-19 pandemic' in the journal Pain Reports 2021, states that COVID-19 also causes peripheral or central neurological complications of neuropathic pain. Increased complications of COVID-19 including in particular Guillain-Barré syndrome, myelitis, and stroke are reviewed with regards to their potential risk of chronic neuropathic pain. This increase in the prevalence of chronic neuropathic pain after COVID-19 is another reason boosting the market growth.
Traditional therapy for pain management includes drugs and medicine, but due to the side effects associated with drugs, people are shifting towards neurostimulation pain management devices to overcome neuropathic pain. Thus because of the above-mentioned reasons neuropathic pain management devices segment is witnessing the largest share in this pain management devices segment.
North America is Expected to Dominate the Pain Management Devices Market
North America has dominated the pain management devices market and is expected to dominate this market due to the presence of advanced technology, key market players, and the large incorporation of pain management devices in ambulatory centers.The United States accounts for the increasing number of individuals suffering from pain. For instance, the Journal of Pain and Palliative Therapy, 2021 accounts that approximately 20.28% of the United States population is suffering from chronic pain and 5% of this population comprises adults who are suffering from high-impact chronic pain. Therefore, with the increasing prevalence of the population suffering from chronic pain in the United States rapidly drives its market for pain management devices. Also due to the high prevalence of neuropathic pain and higher incidence of the chronic disease reported in the United States, the population there is more dependent on pain management devices rather than on medicines. For instance, according to an article in the journal Pain Medicine, about 2% of the United States population suffers from neuropathic pain. Additionally, as the article in journal International Journal of Environmental Health and Public Resource, 2021 mentioned that approximately 45%, (or 133 million) of all Americans suffer from at least one chronic disease thus due to the high prevalence of population in North America suffering from chronic diseases. The increase in patient population suffering from pain will in turn propel the market growth.
Due to high growth potential, a significant increase in the patient base population, and high disposable income the demand of the pain management devices market is expected to increase during the forecast period.
Pain Management Devices Industry Overview
The pain management devices market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The existing key players in the market are Abbott lab, AstraZeneca PLC, Baxter International Inc, DJO Global LLC, SPR Therapeutics, Stim Wave LLC, LivaNova, Nevro Corp, Innovis, ICU Medical Inc, and other prominent players.Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION( Market Size by Value)
6 COMPETITIVE LANDSCAPE
Methodology
LOADING...
